GSK's Blenrep (belantamab mafodotin) has officially been approved by the UK's Medicines and Healthcare products Regulatory ...

UK pharma major GSK on Friday announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Blenrep (belantamab mafodotin) in combinations with bortezomib plus ...

LONDON, UK I April 17, 2025 I GSK plc (LSE/NYSE: GSK) today announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency ...

The London-based pharmaceutical company said Blenrep, or belantamab mafodotin, was approved for the treatment of adult patients with multiple myeloma in combination with bortezomib plus dexamethasone, ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

Cancer treatments can instigate ocular surface disease and other deleterious ocular side effects that optometrists can oversee and manage.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

When Mateo Mejia Saldarriaga, MD, first started seeing multiple myeloma (MM) patients as a medical student in his native Colombia 10 years ago, he was intrigued by the multifaceted nature of this ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Shortly after President Donald Trump won his second presidential election in the U.S. last fall, British drugmaker GSK came to federal prosecutors in New York, bearing intel from employees ...

GSK is studying a group of more than a million older adults in the UK to see if its shingles vaccine lowers the risk of dementia. The British drugs group, led by boss Emma Walmsley, is using the ...